Lower sales price ceilings and impact on revenue due to revisions to the National Health Insurance drug price standard
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2020: 31 of 70 companies on the "Worse" side.
51 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The impact of regular reductions in the National Health Insurance drug price standard on sales price ceilings and revenue continues to be disclosed. - FY2025-H1RestatedAnnual report
「The filing states that, during the interim consolidated accounting period, there were no material changes in the major risks that management recognizes could materially affect the consolidated companies' financial position, operating results or cash flows, or in the matters described under Business Risks in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2022RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, continues to be disclosed. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2022-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2021RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, continues to be disclosed. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2020RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, continues to be disclosed. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2020-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2019RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, continues to be disclosed. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2019-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2018RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, continues to be disclosed. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2018-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2017RestatedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, is reiterated. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing broadly states that there have been no material changes concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The filing states that there have been no material changes from the risks described in the previous fiscal year concerning lower sales price ceilings and the impact on revenue due to revisions to the National Health Insurance drug price standard. - FY2016First statedAnnual report
「The National Health Insurance drug price standard is generally revised once every 2 years to reflect prevailing market prices, and is lowered each time it is revised. Accordingly, the ceiling on sales prices also declines with each revision to the drug price standard, affecting revenue.」
The risk that the National Health Insurance drug price standard is generally revised downward once every 2 years, affecting sales price ceilings and revenue, is disclosed.